Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Trial of bacTRL-IL-12 in Advanced Solid Tumours
NCT04025307Phase 1Terminated
- Sponsor
- IQVIA
- Start
- Aug 2019
- Primary completion
- Dec 2020
- Modality
- Cytokines & Interferons, Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bacTRL-IL-12 in solid tumor, sponsored by IQVIA. Primary endpoint: Incidence and severity of adverse events at Day 31. Started Aug 2019; status: terminated.
02
Drugs
bacTRL-IL-12
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04025307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04025307.